Evidence map›Paper›PMID 37932451›Full record

ArticleNature structural & molecular biology2023

CRISPR-Cas9-based functional interrogation of unconventional translatome reveals human cancer dependency on cryptic non-canonical open reading frames.

Caishang Zheng, Yanjun Wei, Peng Zhang, Kangyu Lin, Dandan He, Hongqi Teng, Ganiraju Manyam, Zhao Zhang, Wen Liu, Hye Rin Lindsay Lee and 16 more

Open access · hybridAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Finding functional microproteins.Trends in genetics : TIG · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Microproteins unveiling new dimensions in cancer.Functional & integrative genomics · 2024
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 2 countries.

Caishang Zheng *Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yanjun Wei *Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4200-2859
Peng ZhangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kangyu LinDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dandan HeDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hongqi TengDepartment of Experimental Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ganiraju ManyamDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhao ZhangDepartment of Biochemistry and Molecular Biology, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.
Wen LiuCenter for Infectious and Inflammatory Diseases, Texas A&M Health Science Center, Institute of Biosciences of Technology, Houston, TX, USA.ORCID 0000-0002-4804-2918
Hye Rin Lindsay LeeDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Ximing TangDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wei HeDepartment of Epigenetics and Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nelufa IslamMass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-9487-4635
Antrix JainMass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-2815-3645
Yulun ChiuDepartment of Melanoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shaolong CaoDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yarui DiaoDepartment of Cell Biology, Duke University Medical Center, Durham, NC, USA.
Sherita Meyer-GauenDepartment of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0001-9905-1494
Magnus HöökCenter for Infectious and Inflammatory Diseases, Texas A&M Health Science Center, Institute of Biosciences of Technology, Houston, TX, USA.
Anna MalovannayaMass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX, USA.
Wenbo LiDepartment of Biochemistry and Molecular Biology, McGovern Medical School, the University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0002-9042-5664
Ming HuDepartment of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.ORCID 0000-0003-0987-2916
Wenyi WangDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-0617-9438
Han XuDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8654-461X
Scott KopetzDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yiwen ChenDepartment of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. ychen26@mdanderson.org.ORCID 0000-0002-7706-7540
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USCleveland Clinic · USTexas A&M Health Science Center · USDuke University · USFudan University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Computational approaches for protein functional analysis using CRISPR screensR35GM137927 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI XU, HAN · 2020 to 2024
$2.0M
Systematic dissection of function and mechanism of long non-coding RNAs in glioblastomaR01NS117668 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YIWEN · 2021 to 2025
$2.0M
Integrative approaches for decoding the function and regulation of unconventional RNA translationR01GM130838 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, YIWEN · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA221707NIGMS NIH HHS R01 GM130838NIGMS NIH HHS R35 GM137927NINDS NIH HHS R01 NS117668
6 · The paper itself

Abstract

Emerging evidence suggests that cryptic translation beyond the annotated translatome produces proteins with developmental or physiological functions. However, functions of cryptic non-canonical open reading frames (ORFs) in cancer remain largely unknown. To fill this gap and systematically identify colorectal cancer (CRC) dependency on non-canonical ORFs, we apply an integrative multiomic strategy, combining ribosome profiling and a CRISPR-Cas9 knockout screen with large-scale analysis of molecular and clinical data. Many such ORFs are upregulated in CRC compared to normal tissues and are associated with clinically relevant molecular subtypes. We confirm the in vivo tumor-promoting function of the microprotein SMIMP, encoded by a primate-specific, long noncoding RNA, the expression of which is associated with poor prognosis in CRC, is low in normal tissues and is specifically elevated in CRC and several other cancer types. Mechanistically, SMIMP interacts with the ATPase-forming domains of SMC1A, the core subunit of the cohesin complex, and facilitates SMC1A binding to cis-regulatory elements to promote epigenetic repression of the tumor-suppressive cell cycle regulators encoded by CDKN1A and CDKN2B. Thus, our study reveals a cryptic microprotein as an important component of cohesin-mediated gene regulation and suggests that the 'dark' proteome, encoded by cryptic non-canonical ORFs, may contain potential therapeutic or diagnostic targets.

Indexed as

CRISPR-Cas SystemsNeoplasmsAnimalsHumansOpen Reading FramesProteomeProteome

Identifiers

PMID37932451
PMCPMC10716047
OpenAlexW4388409328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.